Based on the analysis of Adicet Bio's profitability, liquidity, and operating efficiency, Adicet Bio is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January. At this time, Adicet Bio's Net Invested Capital is comparatively stable compared to the past year. Net Working Capital is likely to gain to about 200.3 M in 2024, whereas Current Deferred Revenue is likely to drop slightly above 3.6 M in 2024. Key indicators impacting Adicet Bio's financial strength include:
Investors should never underestimate Adicet Bio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Adicet Bio's cash flow, debt, and profitability to make informed and accurate decisions about investing in Adicet Bio.
Net Income
(135.53 Million)
Adicet
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Operating Cycle
Cash Conversion Cycle
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Inventory
Dividends Paid
Sale Purchase Of Stock
Investments
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Good Will
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Intangible Assets
Common Stock
Net Receivables
Non Currrent Assets Other
Short Term Debt
Capital Lease Obligations
Net Invested Capital
Property Plant And Equipment Gross
Non Current Liabilities Other
Net Working Capital
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling And Marketing Expenses
Net Interest Income
Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Adicet Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Adicet Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Adicet Bio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Adicet Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adicet Bio. Check Adicet Bio's Beneish M Score to see the likelihood of Adicet Bio's management manipulating its earnings.
Adicet Bio Stock Summary
Adicet Bio competes with Edgewise Therapeutics, Cullinan Oncology, Vor Biopharma, Tenaya Therapeutics, and Bicycle Therapeutics. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people.
Comparative valuation techniques use various fundamental indicators to help in determining Adicet Bio's current stock value. Our valuation model uses many indicators to compare Adicet Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adicet Bio competition to find correlations between indicators driving Adicet Bio's intrinsic value. More Info.
Adicet Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Adicet Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adicet Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Adicet Bio Systematic Risk
Adicet Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Adicet Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Adicet Bio correlated with the market. If Beta is less than 0 Adicet Bio generally moves in the opposite direction as compared to the market. If Adicet Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Adicet Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Adicet Bio is generally in the same direction as the market. If Beta > 1 Adicet Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Adicet Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adicet Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Adicet Bio growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Adicet Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adicet Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Adicet Bio based on widely used predictive technical indicators. In general, we focus on analyzing Adicet Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adicet Bio's daily price indicators and compare them against related drivers.
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.